Bin, T.;                     Wang, Y.;                     Tang, J.;                     Xu, X.-J.;                     Lin, C.;                     Lu, B.    
        Prognostic Risk Model of Megakaryocyte–Erythroid Progenitor (MEP) Signature Based on AHSP and MYB in Acute Myeloid Leukemia. Biomedicines 2025, 13, 1845.
    https://doi.org/10.3390/biomedicines13081845
    AMA Style
    
                                Bin T,                                 Wang Y,                                 Tang J,                                 Xu X-J,                                 Lin C,                                 Lu B.        
                Prognostic Risk Model of Megakaryocyte–Erythroid Progenitor (MEP) Signature Based on AHSP and MYB in Acute Myeloid Leukemia. Biomedicines. 2025; 13(8):1845.
        https://doi.org/10.3390/biomedicines13081845
    
    Chicago/Turabian Style
    
                                Bin, Ting,                                 Ying Wang,                                 Jing Tang,                                 Xiao-Jun Xu,                                 Chao Lin,                                 and Bo Lu.        
                2025. "Prognostic Risk Model of Megakaryocyte–Erythroid Progenitor (MEP) Signature Based on AHSP and MYB in Acute Myeloid Leukemia" Biomedicines 13, no. 8: 1845.
        https://doi.org/10.3390/biomedicines13081845
    
    APA Style
    
                                Bin, T.,                                 Wang, Y.,                                 Tang, J.,                                 Xu, X.-J.,                                 Lin, C.,                                 & Lu, B.        
        
        (2025). Prognostic Risk Model of Megakaryocyte–Erythroid Progenitor (MEP) Signature Based on AHSP and MYB in Acute Myeloid Leukemia. Biomedicines, 13(8), 1845.
        https://doi.org/10.3390/biomedicines13081845